Molecular and Cellular Biology of Thrombopoietin
血小板生成素的分子和细胞生物学
基本信息
- 批准号:7652101
- 负责人:
- 金额:$ 37.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1995
- 资助国家:美国
- 起止时间:1995-06-01 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingBenignBindingBlood PlateletsCell LineCell SurvivalCellsClassificationCongenital DisordersDevelopmentEndocytosisEndosomesErythroid CellsErythropoiesisErythropoietinErythropoietin ReceptorEtiologyFinancial compensationHemorrhagic ThrombocythemiaKnockout MiceLigandsLinkLysosomesMAP Kinase GeneMeasuresMegakaryocytopoiesesModelingMolecular and Cellular BiologyMusMutateMutationMyeloproliferative diseasePathway interactionsPatientsPeptidesPhosphorylationPhosphotyrosinePhysiologyPlatelet Count measurementPolycythemia VeraPrimary MyelofibrosisProcessProductionProteinsRecyclingRegulationResidual stateRoleSignal TransductionSurfaceThrombocytopeniaThrombopoiesisThrombopoietinTyrosineUbiquitinationWorkcancer cellcell growth regulationcytokineglycosylationhuman MPL proteininsightleukemialoss of functionmimeticsmulticatalytic endopeptidase complexneoplasticpreventprogenitorprotein protein interactionpublic health relevancereceptorreceptor sensitivityresponsesrc Homology Region 2 Domaintooltrafficking
项目摘要
DESCRIPTION (provided by applicant): Thrombopoietin (TPO) is the primary regulator of thrombopoiesis. Through its interaction with the c-Mpl receptor, TPO initiates a signaling cascade by triggering the phosphorylation and activation of Jak2. Although this is well established, it remains unclear as to how TPO signaling is modulated, which has important consequences for the regulation of cell growth and differentiation. Dysregulation of TPO signaling, as exemplified by mutations conferring constitutive activity to Jak2 or c-Mpl, is known to underlie the development of congenital and acquired myeloproliferative disorders (MPDs), including polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF). In addition, TPO-mimetics are emerging as important tools for the treatment of patients with thrombocytopenia of both benign and neoplastic etiologies. In this competitive renewal we propose to study the regulation of TPO signaling, including: 1) c-Mpl receptor trafficking and internalization in response to TPO, 2) regulation of c-Mpl degradation and its consequences for TPO signaling, and 3) functional similarities and differences between TPO and erythropoietin (EPO) signaling. PUBLIC HEALTH RELEVANCE: In this renewal of "The molecular and cellular biology of thrombopoeitin" we propose to build on our previous work on the mechanisms of thrombopoietin signaling. In particular we will study the physiology of c-Mpl receptor trafficking, pathways that regulate degradation of c-Mpl, and functional similarities and differences between Thrombopoietin and erythropoietin signaling. The results of these studies will provide new insights into the role of thrombopoietin signaling in normal as well as malignant cells.
描述(由申请人提供):血小板生成素(TPO)是血小板生成的主要调节剂。通过与c-Mpl受体的相互作用,TPO通过触发Jak 2的磷酸化和活化来启动信号级联。虽然这是很好地建立,它仍然不清楚TPO信号是如何调制的,这对细胞生长和分化的调节具有重要的后果。已知TPO信号传导的失调,如赋予Jak 2或c-Mpl组成型活性的突变所例示的,是先天性和获得性骨髓增生性疾病(MPD)的发展的基础,包括真性红细胞增多症(PV)、原发性血小板增多症(ET)和特发性骨髓纤维化(IMF)。此外,TPO模拟物正在成为治疗良性和肿瘤性血小板减少症患者的重要工具。在这种竞争性更新中,我们建议研究TPO信号传导的调节,包括:1)c-Mpl受体响应于TPO的运输和内化,2)c-Mpl降解的调节及其对TPO信号传导的后果,以及3)TPO和促红细胞生成素(EPO)信号传导之间的功能相似性和差异。公共卫生关系:在这个更新的“血小板生成素的分子和细胞生物学”,我们建议建立在我们以前的工作机制血小板生成素信号。特别是,我们将研究c-Mpl受体运输的生理学,调节c-Mpl降解的途径,以及血小板生成素和促红细胞生成素信号传导之间的功能相似性和差异。这些研究的结果将为血小板生成素信号在正常和恶性细胞中的作用提供新的见解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AMY E GEDDIS其他文献
AMY E GEDDIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AMY E GEDDIS', 18)}}的其他基金
ANTI-IDIOTYPE MONOCLONAL ANTIBODY AS A TUMOR VACCINE FOR NEUROBLASTOMA
抗独特型单克隆抗体作为神经母细胞瘤的肿瘤疫苗
- 批准号:
7205566 - 财政年份:2003
- 资助金额:
$ 37.08万 - 项目类别:
Anti-Idiotype MAB as a Tumor Vaccine for Neuroblastoma
抗独特型 MAB 作为神经母细胞瘤肿瘤疫苗
- 批准号:
7045384 - 财政年份:2003
- 资助金额:
$ 37.08万 - 项目类别:
THE ROLE OF PL3K IN THROMBOPOIETIN SIGNALING
PL3K 在血小板生成素信号传导中的作用
- 批准号:
6597567 - 财政年份:2001
- 资助金额:
$ 37.08万 - 项目类别:
THE ROLE OF PL3K IN THROMBOPOIETIN SIGNALING
PL3K 在血小板生成素信号传导中的作用
- 批准号:
6856480 - 财政年份:2001
- 资助金额:
$ 37.08万 - 项目类别:
THE ROLE OF PL3K IN THROMBOPOIETIN SIGNALING
PL3K 在血小板生成素信号传导中的作用
- 批准号:
6683245 - 财政年份:2001
- 资助金额:
$ 37.08万 - 项目类别:
THE ROLE OF PL3K IN THROMBOPOIETIN SIGNALING
PL3K 在血小板生成素信号传导中的作用
- 批准号:
6226398 - 财政年份:2001
- 资助金额:
$ 37.08万 - 项目类别:
THE ROLE OF PL3K IN THROMBOPOIETIN SIGNALING
PL3K 在血小板生成素信号传导中的作用
- 批准号:
6721328 - 财政年份:2001
- 资助金额:
$ 37.08万 - 项目类别:
Molecular and Cellular Biology of Thrombopoietin
血小板生成素的分子和细胞生物学
- 批准号:
7624000 - 财政年份:1995
- 资助金额:
$ 37.08万 - 项目类别:
Molecular and Cellular Biology of Thrombopoietin
血小板生成素的分子和细胞生物学
- 批准号:
8218783 - 财政年份:1995
- 资助金额:
$ 37.08万 - 项目类别:
Molecular and Cellular Biology of Thrombopoietin
血小板生成素的分子和细胞生物学
- 批准号:
8496504 - 财政年份:1995
- 资助金额:
$ 37.08万 - 项目类别:
相似海外基金
Genome analysis-based prediction model development for response to stereotactic radiosurgery in benign brain tumors
基于基因组分析的预测模型开发,用于良性脑肿瘤立体定向放射外科治疗的反应
- 批准号:
23K08495 - 财政年份:2023
- 资助金额:
$ 37.08万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
高风险良性乳腺诊断女性的临床乳腺癌风险预测模型
- 批准号:
10719777 - 财政年份:2023
- 资助金额:
$ 37.08万 - 项目类别:
Environmentally Benign Precise Transformations of Alkenes by Chiral Chalcogenide Catalysts
手性硫属化物催化剂对环境无害的烯烃精确转化
- 批准号:
22KJ2498 - 财政年份:2023
- 资助金额:
$ 37.08万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Learners to LeAders in benign Urology, benign Nephrology, and non-Cancer Hematology
良性泌尿外科、良性肾脏病学和非癌症血液学领域的学习者和领导者
- 批准号:
10726042 - 财政年份:2023
- 资助金额:
$ 37.08万 - 项目类别:
The role of estrogen receptor alpha in prostatic fibrosis contributing to benign prostatic hyperplasia
雌激素受体α在导致良性前列腺增生的前列腺纤维化中的作用
- 批准号:
10607151 - 财政年份:2023
- 资助金额:
$ 37.08万 - 项目类别:
Development of a medical device to resolve benign esophageal stricture by heating and traction
开发通过加热和牵引解决良性食管狭窄的医疗设备
- 批准号:
23H03765 - 财政年份:2023
- 资助金额:
$ 37.08万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of benign/malignant differentiation method for thyroid follicular tumor using organoids
利用类器官开发甲状腺滤泡性肿瘤良恶性鉴别方法
- 批准号:
23K08075 - 财政年份:2023
- 资助金额:
$ 37.08万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis
p53在散发性肿瘤发生良性向恶性转变中的参与和作用机制
- 批准号:
10720034 - 财政年份:2023
- 资助金额:
$ 37.08万 - 项目类别:
I-Corps: Mitigating Multidrug Resistant Bacterial Infections with Biocompatible and Environmentally Benign Nanoantibiotics
I-Corps:利用生物相容性且对环境无害的纳米抗生素减轻多重耐药细菌感染
- 批准号:
2306943 - 财政年份:2023
- 资助金额:
$ 37.08万 - 项目类别:
Standard Grant
Towards Achieving Zero Emissions through the use of an Environmentally Benign Non-Regenerable Solvent to Capture CO2 from Large Point Source Emitters for Direct Permanent Storage in Geological Formation or Usage in Accelerated Curing of Ready-mix Con
通过使用环境友好的不可再生溶剂从大型点源排放器捕获二氧化碳,直接永久储存在地质构造中或用于预拌混凝土的加速固化,从而实现零排放
- 批准号:
RGPIN-2022-03431 - 财政年份:2022
- 资助金额:
$ 37.08万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




